MONTREAL, June 29, 2011 – Aptilon Corporation (“Aptilon” or the “Company”) (TSX-V: APZ), a leader in online access to, engagement and interaction with physicians and healthcare professionals on behalf of pharmaceutical and life sciences companies, today announced its financial results for the three-month period ended March 31, 2011. Financial references are in CDN dollars. Complete financial statements and MD&A are available on SEDAR at www.sedar.com.

Highlights:

  • First quarterly report completed following successful conversion to International Financial Reporting Standards (“IFRS”).
  • Initiated delivery updates of its product line and ‘cloud’ based services designed to increase opportunities to access, engage and interact with healthcare professionals via any channel and any device. These updates are expected to continue in the second quarter and positively impact the Company’s results in the second half of 2011.
  • Revenue for the three-month period ended March 31, 2011 reached $7.2 million, a decrease of 6% from $7.66 million during the same period a year earlier.  Most of the change was attributed to the strengthening value of the Canadian dollar compared to the US dollar.
  • Gross margin was maintained at approximately 54% in the quarter, reaching $3.9 million from $4.2 million in the same quarter a year earlier.
  • Operating expenses in the period decreased 9% to $3.36 million from $3.68 million in the first quarter of 2010.
  • Quarterly comprehensive net income improved 6% to a loss of $0.64 million from a loss of $0.68 million during the same period a year earlier.
  • Generated positive net cash flow from operations of $1.54 million reversing the cash used by operations of $0.55 million in the prior year.

Subsequent to the end of the period, the Company successfully extended the repayment period of the secured promissory note in the amount of US$27,200,000 issued in September 2009 in connection with the purchase of substantially all the assets of Direct Medical Data, LLC and BLM Incorporated related to their healthcare marketing services. The original note provided for monthly installments, and a lump sum payment of approximately US$12,417,000 on September 15, 2012. The original note and associated lump sum payments were replaced by a new secured promissory note in the amount of US$21,750,000, being the balance due under the original note as of April 14, 2011. The new note bears interest at the rate of 6.9% per annum and is repayable in increasing monthly installments (ranging from US$226,000 for the first 9 months to US$600,000 for 11 of the last 12 months) from April 15, 2011 until December 15, 2015. It is secured and guaranteed in the same manner as the original note.

About Aptilon Corporation

Aptilon enables pharmaceutical, biotech and medical device companies to effectively reach, message, connect and interact with US physicians and healthcare professionals on the Internet and over mobile devices via multiple access channels. Its innovative service offerings provide targeted impressions and interactions through: video and mobile detailing, ReachNetSM Physician Access Channel, the DMD database and permission-based email services. Top US pharmaceutical companies and respected healthcare organizations have adopted Aptilon’s solutions to market to, engage and interact with leading healthcare practitioners. For more information, visit .

ReachNetSM is a service mark of Aptilon Corporation.

Forward-looking statements

This news release may contain forward-looking statements. These statements relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management of Aptilon. A number of factors could cause actual events, performance or results to differ materially from the events performance and results discussed in the forward-looking statements. These forward-looking statements are made as of the date hereof and Aptilon does not assume any obligation to update or revise them to reflect new events or circumstances.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

-30-

For further information please contact:

Mr. Denis Martineau

President

Aptilon Corporation

1-888-544-8866

investors@aptilon.com